Journal of Oncology

Journal of Oncology / 2019 / Article

Corrigendum | Open Access

Volume 2019 |Article ID 7921582 | 1 page | https://doi.org/10.1155/2019/7921582

Corrigendum to “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer”

Received02 Jul 2019
Accepted04 Jul 2019
Published21 Aug 2019

In the article titled “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer” [1], Drs. Jameel Muzaffar, Ahmad M. Haider, and Marjorie Adams Curry were missing from the authors’ list.

Dr. Jameel Muzaffar, MD, was responsible for manuscript guidance and preparation.

Dr. Ahmad M. Haider was responsible for statistical analysis and chart preparation.

Dr. Marjorie Adams Curry was responsible for providing partial list of patients who were treated with PDL1 inhibitors.

The corrected authors’ list is shown above, and it has been added in-line to the published article.

References

  1. S. Bari, J. Muzaffar, A. Chan et al., “Outcomes of programmed cell death protein 1 (PD-1) and programmed death-ligand 1(PD-L1) inhibitor therapy in HIV patients with advanced cancer,” Journal of Oncology, vol. 2019, Article ID 2989048, 5 pages, 2019. View at: Publisher Site | Google Scholar

Copyright © 2019 Shahla Bari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

535 Views | 193 Downloads | 2 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.